We’re on a mission!
MY01 Inc. is on a mission to empower healthcare professionals with the ability to pre-empt severe medical conditions thereby improving patient outcomes.
We believe that adding actionable quantitative data at the bedside during these interactions is the best way to make a meaningful impact to the patient while improving the experience of providing care. MY01 Inc. focuses on delivering actionable data at the bedside to augment clinical assessments. Qualitative People to People Assessments are at the core of personalized healthcare.
Growing since
2015
Employees
40
Nationalities in Our Team
20
Degrees
64
Physician-Patient engagement is key to effective healthcare.
Healthcare is human.
Our founders
Edward Harvey, MDCM
Chief Medical Officer
Bio
Charles Allan, M.Eng
Chief Executive Officer
Bio
George Xereas, PhD
Chief Technology Officer
Bio
Dr. Edward J. Harvey has a rich history of collaboration with basic, clinical and engineering scientists. He is a tenured Professor of Surgery at McGill University. He is the trauma research program leader at the Research Institute of the McGill University Health Centre (RI-MUHC) with over 60 investigators in his group. He is, or has been, editor-in-chief of the Canadian Journal of Surgery; editorial board member of the Journal of Orthopaedic Trauma and OTA International; chairman of the Research Committee and the Annual meeting program chair for the Orthopedic Trauma Association; chair of the Trauma Section at the Orthopaedic Research Society; and president of the Canadian Orthopaedic Association amongst other national and international positions.
Charles is passionate about using really small things to solve big problems. Being surrounded by many successful and supportive entrepreneurs, he quickly gained an ability to create teams and transform problems into solutions.
An example of his passion at work can be found during his undergraduate years at Queens University, where he helped build a microfluidic pump for an implantable therapeutic for glaucoma. This project helped ignite his entrepreneurial spirit, and, while pursuing his Masters in Bioelectrical Engineering at McGill University, he formed a team that combined engineering and technology to develop microsolutions. Some of those initial microsystems are the foundational components used by the three companies that Charles founded: MY01, Inc., Stathera, Inc., and NXTSENS Microsystems, Inc. These companies each have won several awards and been selected for important growth accelerators. They have grown to over 70 employees, and combined to raise over $50M in funding.
George Xereas is the Chief Technology Officer at MY01 Inc. In this role, he leads the company’s technology and product development. Prior to MY01 Inc., he served as the Chief Technology Officer for NXTSENS Microsystems Inc., a fabless MEMS based sensor company he co-founded. George obtained his PhD in Electrical and Electronics Engineering from McGill University in 2017, which was supported by the Les Vadasz Doctoral Fellowship in Engineering – Intel. George is an author in 19 high impact publications in MEMS sensors, and is an inventor in 14 utility patents.
Timeline
March 2019
Company Incorporation
What started off as a Master’s project at McGill University, in March 2015, became an official startup as our founders: Charles, Ed, and George, officially registered the project as a corporate entity.
January 2020
CE Mark
MY01 receives positive notice from the European Commission to start selling our device across the European Union.
July 2020
FDA Clearance Granted
MY01 received its 510k clearance from the Food & Drug Administration (FDA) for its MY01 Continous Compartmental Pressure Monitor.
October 2021
Breakthrough Device Designation Granted
MY01 Inc. received its first-ever “Breakthrough Device” designation from the FDA, joining a select list of Orthopaedic companies to receive this designation since the program began in 2016.
December 2022
COTS Study
Completion of the clinical study surrounding the safety and functionality of MY01 in patients at risk for developing compartment syndrome. The trials were done in 6 sites across Canada from the largest level 1 trauma centers of the country.
April 2023
Quebec Study
The completion of the clinical study was used as a feasibility and safety trial to establish a baseline for pressures and what should be pressure triggers for surgical release (aka a fasciotomy).
April 2023
MY01 receives $12.5M USD Funding
The Series A funding round, led by Investissement Quebec along with Desjardins Capital and Fondaction, was raised to expand commercial- ization activities in the United States and accelerate growth.
September 2023
1K Devices Milestone
The MY01 device sets the gold standard for aiding in diagnosing compartment syndrome by surpassing a 1000 case milestone which highlights its vital role in enhancing clinical assessments.